Early Mortality in Elderly Patients With Newly Diagnosed Multiple Myeloma Treated With Novel Agents

Alessandra Larocca,Sara Bringhen,Maria Teresa Petrucci, Massimo Offidani,Giulia Benevolo,Monica Galli, Francesca Patriarca,Stelvio Ballanti,Carmela Palladino,Norbert Pescosta,Mariella Grasso,Andrea Evangelista,S Spada,Sara Pezzati,Stefano Pulini,A Bernardini,Delia Rotascalabrini, Fortunato Morabito,Piero Tosi, S P Oliva, M Baldini,Roberto Marasca,Paola Finsinger,Claudia Cellini,Roberto Ria,Gabriele Aitoro,Roman Hajek, Mario Boccadoro, Antonio Palumbo

Clinical Lymphoma Myeloma and Leukemia（2015）

Cited 6|Views20

No score

Abstract

Early mortality in multiple myeloma (MM) is due to the effects of active disease, comorbidities and treatment-related complications. With conventional chemotherapy, early toxic deaths were 10% in the first 2 months. Novel agents have improved MM outcome at the expense of newer toxicity. We have studied early deaths in a series of patients treated with novel agents and enrolled in 2 phase 3 trials to assess the rate and the causes of toxic deaths.

Translated text

Key words

multiple myeloma treated,multiple myeloma,elderly patients,mortality

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined